RE:RE:RE:RE:RE:Warrant $$$ coming soonGood points ScienceFirst. Stated in the news release of Dec 9/21 Arkady Mandel again discussed GBM & NSCLC which leads me to believe within 6 months we will see the start of movement towards PH1 of both indications unless this Covid-19 continues to slow progression of NMIBC with enrollment.
Arkady Mandel, M.D., Ph.D., D.Sc., Interim Chief Executive Officer (“CEO”) and Chief Scientific Officer (“CSO”), Theralase®, stated that, “This patent is strategic to opening up new international opportunities for Theralase® by expanding its IP portfolio of medical laser and oncology focused technologies internationally. Theralase®’s long-term strategy is to commercialize the Anti-Cancer Therapy (“ACT”) division technology commencing with NMIBC and expanding into Glio Blastoma Multiforme (“GBM”), Non-Small Cell Lung Cancer (“NSCLC”) and other various cancer indications to provide a safe, effective and rapid alternative treatment option for patients inflicted with these deadly diseases. The ability to provide personalized treatment for cancer patients to 'hunt and destroy' their cancer and prevent its recurrence and progression, all in a single or dual treatment, remains at the forefront of our research and development objectives.” ScienceFirst wrote
Just like we have done them in order to proceed with a Ph. 1b with TLD-1433, there are at least things that must be fulfilled for each GBM and NSCLC trials in order to move further:
1) A MSAB has to back the design of each of these trials.
Just like we onboarded urology specialists like Dr. Kamat, Dr, OMDonnell, Dr. Jewett, etc ... So we'll have to see pulmonary and brain specialists join our MSAB before we can expect these trials to move forward as they will be them that will give the credibility to our Ph. 1b trial and enrollment process.
2) HC/FDA approval of any equipment to be used with the treatment (ref.: February 9, 2015)
3) Manufacturing of Rutherrin
4) shelf-life stability demonstration of Rutherrin (go back to press releases to see what has been done on that for TLD-1433)
5) GMP manufacturing of Rutherrin
6) GLP Toxicology Analysis of Rutherrin
7) Review Ethics Board of clinical sites
8) file an Investigational Testing Authorization (“ITA”) with HC/FDA filed an Investigational Testing Authorization (“ITA”) with Health Canada for approval to use its patent pending TLC-3200 Photo Dynamic Therapy (“PDT”) Laser System and TLC-34XX Dosimetry Fibre Optic Cage (“DFOC”) technology, in conjunction with its Clinical Trial Application (“CTA”) approved lead PDC, TLD-1433, in a Phase Ib clinical trial for the treatment of Non-Muscle Invasive Bladder Cancer (“NMIBC”).
These were all announced leading to our NMIBC Ph. 1b. There are some that might not need to be announced for NSCLC or GBM, but clearly, some will have to. ___________________________
Oilminerdeluxe - (1/2/2022 2:48:54 PM) RE:RE:RE:Warrant $$$ coming soon Start the freaking GBM trial. Patience, breathe, patience, breathe.